Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias

References

• AbdelkefiALadebSTorjmanL2008Single autologous stem cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicentre randomized clinical trialBlood11118051017875806
   PubMed Web of Science ®Google Scholar
• AndersonKRichardsonPChanan-KhanA2006Single-agent Bortezomib in previously untreated multiple myeloma (MM): Results of a phase II multicenter study [abstract]J Clin Oncol18S7504
   Google Scholar
• AttalMHarousseasuJLLeyvrazS2006Maintenance therapy with thalidomide improves survival in multiple myeloma patientsBlood10832899416873668
   PubMed Web of Science ®Google Scholar
• BadrosAZGoloubevaORapoportAP2005Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patientsJ Clin Oncol2340899915867202
   PubMed Web of Science ®Google Scholar
• BensingerWJagannathABeckerP2006Phase I dose escalation study of a fully human, antagonist anti-CD40 antibody, HCD122 (Formerly CHIR-12.12) in patients with relapsed and refractory multiple myeloma [abstract]Blood1083575
   Web of Science ®Google Scholar
• BladeJSan MiguelJNaglerA2007The prolonged time to progression with pegylated liposomal doxorubicin + Bortezomib versus Bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure [abstract]Blood110410
   Web of Science ®Google Scholar
• Chanan-KhanAA2004Bcl-2 antisense therapy in multiple myelomaOncology (Huntington)18214
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAARichardsonPGAlsinaM2005Phase 1 clinical trial of KOS-953 + Bortezomib (BZ) in relapsed refractory multiple myeloma (MM) [abstract]Blood10636215774616
   PubMed Web of Science ®Google Scholar
• ChauhanDCatleyLLiG2005A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell84071916286248
   PubMed Web of Science ®Google Scholar
• ChauhanDSinghABrahmandamM2007Combination of protea-some inhibitors Bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myelomaBlood11116546418006697
   PubMed Web of Science ®Google Scholar
• DaviesFERajeNHideshimaT2001Thalidimide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaBlood982101611418482
   PubMed Web of Science ®Google Scholar
• DaviesFEWuPSrikanthM2006The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with minimal toxicity compared to velcade alone (V) and velcade plus dexamethasone [abstract]Blood1083537
   Web of Science ®Google Scholar
• DeocampoRRichRRyooJJ2002Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood1003063712384400
   PubMed Web of Science ®Google Scholar
• DimopoulosMATsatalasCZomasA2003Treatment of Waldenström’s macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasoneSemin Oncol30265912720150
   PubMed Web of Science ®Google Scholar
• DimopoulosMASpencerAAttalM2005Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM010) [abstract]Blood1066
   Web of Science ®Google Scholar
• DimopoulosMAAnagnostopoulosAKyrtsonisMC2005Treatment of relapsed or refractory Waldenström’s macroglobulinemia with BortezomibHaematologica901655816330439
   PubMed Web of Science ®Google Scholar
• DimopoulosMAnagnostopoulosAKyrtsonisM2006Primary treatment of Waldenströms macroglobulinemia (WM) with dexamethasone, rituximab and cyclophosphamide [abstract]Blood108128
   Web of Science ®Google Scholar
• DredgeKMarriottJBMacdonaldCD2002Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effectsBr J Cancer8711667212402158
   PubMed Web of Science ®Google Scholar
• ElsawaSNovakAKonoplevaM2006Preferential inhibition of malignant cell growth by CDDO in Waldenströms macroglobulinemia [abstract]Blood1082528
   Web of Science ®Google Scholar
• FaconTMaryJHarousseauJ2006Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma [abstract]J Clin Oncol18S1
   Google Scholar
• FrancisLKAlsayedYLeleuX2006Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myelomaClin Cancer Res1268263517121904
   PubMed Web of Science ®Google Scholar
• GertzMAGeyerSMBadrosA2005Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenström’s macroglobulinemiaClin Lymphoma5282415794866
   PubMedGoogle Scholar
• GertzMABloodEKaminerLS2004Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)Leuk Lymphoma4520475515370249
   PubMed Web of Science ®Google Scholar
• GhobrialIMRajkumarSV2003Management of thalidomide toxicityJ Support Oncol119420515334875
   PubMedGoogle Scholar
• GhobrialIFonsecaRGreippPR2004Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenström macroglobulinemia: an Eastern Cooperative Oncology Group StudyCancer1012593815493038
   PubMed Web of Science ®Google Scholar
• HarousseauJLAttalMLeleuX2006Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II studyHaematologica91149850517043025
   PubMed Web of Science ®Google Scholar
• HatjiharissiEHoAXuL2006Preclinical in vitro and in vivo evidence support a therapeutic role for the CD70 directed monoclonal antibody (SGN-70) in Waldenströms macroglobulinemia (WM) [abstract]Blood1082490
   Web of Science ®Google Scholar
• HatjiharissiENgoHLeontovicAA2007Proteomic analysis of Waldenström macroglobulinemiaCancer Res6737778417440091
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDShimaY2000Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyBlood9629435011049970
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDPodarK2001Novel therapies targeting the myeloma cell and its bone marrow microenvironmentSemin Oncol286071211740818
   PubMed Web of Science ®Google Scholar
• HideshimaTBergsagelPLKuehlWM2004aAdvances in biology of multiple myeloma: clinical applicationsBlood1046071815090448
   PubMed Web of Science ®Google Scholar
• HideshimaTPodarKChauhanD2004bp38 MAPK inhibition enhances PS-341 (Bortezomib)-induced cytotoxicity against multiple myeloma cellsOncogene2387667615480425
   PubMed Web of Science ®Google Scholar
• HideshimaTCatleyLYasuiH2006Perifosine, an oral bioactive novel alkylphospholipid, inhibts Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cellsBlood10740536216418332
   PubMed Web of Science ®Google Scholar
• HuLShiYHsuJH2003Downstream effectors of oncogenic ras in multiple myeloma cellsBlood10131263512515720
   PubMed Web of Science ®Google Scholar
• HunterZBoxerMKahlB2006Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079 [abstract]J Clin Oncol247523
   Web of Science ®Google Scholar
• HusseinMBerensonJNiesviskyR2006Results of a phase I trial of SGN-40 (Anti-huCd40 mAb) in patients with relapsed multiple myeloma [abstract]Blood1083576
   Google Scholar
• JagannathSBarlogieBBerensonJ2004A phase 2 study of two doses of Bortezomib in relapsed or refractory myelomaBr J Haematol1271657215461622
   PubMed Web of Science ®Google Scholar
• JagannathSRichardsonPGBarlogieB2006Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to Bortezomib aloneHaematologica919293416818280
   PubMed Web of Science ®Google Scholar
• KastritisEAnagnostopoulosARoussouM2007Treatment of light chain (AL) amyloidosis with the combination of Bortezomib and dexamethasoneHaematologica9213515818024372
   PubMed Web of Science ®Google Scholar
• KnopSGereckeCToppM2006Lenalidomide (revlimid), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma first results of a german multicenter Phase I/II trial [abstract]Blood108408
   Web of Science ®Google Scholar
• KumarSRajkumarSV2006Thalidomide and lenalidomide in the treatment of multiple myelomaEur J Cancer4216122216750621
   PubMed Web of Science ®Google Scholar
• LapidotTDarAKolletO2005How do stem cells find their way home?Blood10619011015890683
   PubMed Web of Science ®Google Scholar
• LeleuXXiaoyingJRunnelsJ2007The Akt pathway regulates survival and homing in Waldenström macroglobulinemiaBlood11044172617761832
   PubMed Web of Science ®Google Scholar
• MateosMVHernandezJMHernandezMT2006Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 studyBlood10821657216772605
   PubMed Web of Science ®Google Scholar
• MitsiadesCSMitsiadesNPoulakiV2002Activation of NF-kap-paB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signalling in human multiple myeloma cells: therapeutic implicationsOncogene2156738312173037
   PubMed Web of Science ®Google Scholar
• MitsiadesCSMitsiadesNSMcMullanCJ2006Antimyeloma activity of heat shock protein-90 inhibitionBlood107109210016234364
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiV2002Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood9945253012036884
   PubMed Web of Science ®Google Scholar
• MitsiadesNMcMullanCPoulakiV2004The mTOR inhibitor RAD001 (Everolimus) is active against multiple myeloma cells in vitro and in vivo [abstract]Blood1041496
   Web of Science ®Google Scholar
• MoreauASJiaXNgoHT2007Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenström’s macroglobulinemiaBlood10949647217284528
   PubMed Web of Science ®Google Scholar
• MoreauASJiaXLeleuX2007Simvastatin, an HMG-CoA inhibitor, induces in vitro antitumor activity in Waldenström’s macroglobulinemia [abstract]Hematologica921219
   Web of Science ®Google Scholar
• MoreauPVoillatlBenboubkerL2006Rituximab in CD20 positive multiple myeloma: a prospective study from the IFM group [abstract]Blood1083577
   Web of Science ®Google Scholar
• NgoHHatjiharissiELeleuX2006The CXCR4/SDF-1 axis regulates migration and adhesion in Waldenström macroglobulinemia [abstract]Blood1082418
   Web of Science ®Google Scholar
• O’ConnorOOrlowskiRAlsinaM2006Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies [abstract]Blood1082430
   Web of Science ®Google Scholar
• OrlowskiRZZhuangSHParekhT2006The combination of pegylated liposomal doxorubicin and Bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with Bortezomib alone: results from a planned interim analysis of a randomized phase III study [abstract]Blood10840416790587
   PubMed Web of Science ®Google Scholar
• PalladiniGPerfettiVObiciL2005The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)Blood10529495115572585
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSCaravitaT2006Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialLancet3678253116530576
   PubMed Web of Science ®Google Scholar
• PalumboAFalcoPFalconeA2006Oral revlimid plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: Results of a multicenter phase I/II study [abstract]Blood108800
   Web of Science ®Google Scholar
• PattersonCSoumeraiJHunterZ2006Sildenafil citrate suppresses disease progression in patients with Waldenström’s macroglobulinemiaJ Clin Oncol18S7556
   Google Scholar
• PodarKRaabMSZhangJ2006Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor Enzastaurin (LY317615.HCl)Blood10916697717023575
   PubMed Web of Science ®Google Scholar
• RajeNKumarSHideshimaT2004Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myelomaBlood10441889315319277
   PubMed Web of Science ®Google Scholar
• RajkumarSVFonsecaRDispenzieriA2000Thalidomide in the treatment of relapsed multiple myelomaMayo Clin Proc7589790110994824
   PubMed Web of Science ®Google Scholar
• RajkumarSVHaymanSGertzMA2002Combination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaJ Clin Oncol2043192312409330
   PubMed Web of Science ®Google Scholar
• RajkumarSVHaymanSRLacyMQ2005Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood1064050316118317
   PubMed Web of Science ®Google Scholar
• RajkumarSVBloodEVesoleD2006Eastern Cooperative Oncology Group Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology GroupJ Clin Oncol24431616365178
   PubMed Web of Science ®Google Scholar
• RajkumarSVBloodE2006Lenalidomide and venous thrombosis in multiple myelomaN Engl J Med35420798016696148
   PubMed Web of Science ®Google Scholar
• RajkumarVJacobusSCallanderN2007A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group [abstract]Blood1107417371947
   PubMed Web of Science ®Google Scholar
• RenaudSFuhrPSchweikertGM2006High-dose rituximab and anti-MAG-associated polyneuropathyNeurology66742416534115
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJ2003A phase 2 study of Bortezomib in relapsed, refractory myelomaN Engl J Med34826091712826635
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLWellerE2002Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood1003063712384400
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMW2005aBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med35224879815958804
   PubMed Web of Science ®Google Scholar
• RichardsonPChanan-KhanAAlsinaM2005bSafety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): Interim results of a phase 1 trial [abstract]Blood106361
   Google Scholar
• RichardsonPGMitsiadesCHideshimaT2006aLenalidomide in multiple myelomaExpert Rev Anticancer Ther611657316925483
   PubMed Web of Science ®Google Scholar
• RichardsonPGBloodEMitsiadesCS2006bA randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood10834586416840727
   PubMed Web of Science ®Google Scholar
• RichardsonPGMitsiadesCGhobrialI2006cBeyond single-agent Bortezomib: combination regimens in relapsed multiple myelomaCurr Opin Oncol1859860816988581
   PubMed Web of Science ®Google Scholar
• RichardsonPLonialSJakubowiakJ2006dA multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM) [abstract]Blood1083582
   Web of Science ®Google Scholar
• RoccaroALeleuXSAccoA2008Dual targeting of the proteasome regulates survival and homing in Waldenström’s macroglobulinemiaBlood11147526318316628
   PubMed Web of Science ®Google Scholar
• RoccaroALeleuXMoreauAS2008Resveratrol exerts antiproliferative effect and induces apoptosis in Waldesntrom’s macroglobulinemiaClin Cancer Res1418495818347188
   PubMed Web of Science ®Google Scholar
• RossiJMoreauxJRoseM2006A Phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated Waldenström’s macroglobulinemia (WM) [abstract]Blood1083578
   Web of Science ®Google Scholar
• SanchorawalaVWrightDGRosenzweigM2007Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trailBlood109492616960148
   PubMed Web of Science ®Google Scholar
• San MiguelJSchlagRKhuagevaO2007MMY-3002: A phase 3 study comparing Bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma [abstract]Blood11076
   Web of Science ®Google Scholar
• ShiYGeraJHuL2002Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779Cancer Res6250273412208757
   PubMed Web of Science ®Google Scholar
• SiegelDKrishnanALonialS2006Phase II trial of SCIO-469 as monotherapy (M) or in combination with Bortezomib (MB) in relapsed refractory multiple myeloma (MM) [abstract]Blood108358016882710
   PubMedGoogle Scholar
• SinghalSMehtaJDesikanR1999Antitumor activity of thalidomide in refractory multiple myelomaN Engl J Med34115657110564685
   PubMed Web of Science ®Google Scholar
• SitiaRPalladiniGMerliniG2007Bortezomib in the treatment of AL amyloidosis: targeted therapy?Haematologica921302718024367
   PubMed Web of Science ®Google Scholar
• SpencerAPrinceHMRobertsA2007Thalidomide improve survivals when use after ASCT [abstract]Hematologica92suppl 2S7b.5
   Google Scholar
• TaiYTTongXSantosD2005Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myelomaCancer Res65589890615994968
   PubMed Web of Science ®Google Scholar
• TamburiniJLevyVChaleteixC2005Treatment of Waldenström’s macroglobulinemia with the combination of fludarabine and cyclophosphamide: results in 49 patientsLeukemia191831416121217
   PubMed Web of Science ®Google Scholar
• TreonSBranaganARHunterZ2004aParadoxical increases in serum IgM and viscosity levels following rituximab in Waldenström’s macroglobulinemiaAnn Oncol151481315367407
   PubMed Web of Science ®Google Scholar
• TreonSBranaganAWasiP2004bCombination therapy with rituximab and fludarabine in Waldenström’s macroglobulinemia [abstract]Blood104753
   Web of Science ®Google Scholar
• TreonSPTournilhacOBranaganAR2004cClinical responses to sildenafil in Waldenström’s macroglobulinemiaClin Lymphoma5205715636699
   PubMedGoogle Scholar
• TreonSPEmmanouilidesCKimbyE2005aExtended rituximab therapy in Waldenström’s macroglobulinemiaAnn Oncol16132815598950
   PubMed Web of Science ®Google Scholar
• TreonSHansenMBranaganAR2005bPolymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström’s macroglobulinemiaJ Clin Oncol234748115659493
   PubMed Web of Science ®Google Scholar
• TreonSPGertzMADimopoulosM2006aUpdate on treatment recommendations from the Third International Workshop on Waldenström’s macroglobulinemiaBlood1073442616410453
   PubMed Web of Science ®Google Scholar
• TreonSPSoumeraiJPattersonC2006bBortezomib, dexamethasone and rituximab (BDR) is a highly active regimen in the primary therapy of Waldenström’s macroglobulinemia: planned interim results of WMCTG clinical trial 05–180 [abstract]Blood1082765
   Web of Science ®Google Scholar
• TreonSPGertzMADimopoulosM2006cUpdate on treatment recommendations from the Third International Workshop on Waldenström’s macroglobulinemiaBlood1073442616410453
   PubMed Web of Science ®Google Scholar
• TreonSPSoumeraiJPattersonC2006dImatinib mesylate (Gleevec) is active in relapsed/refractory Waldenströms macroglobulinemia: Planned interim results of WMCTG Clinical Trial 05–140 [abstract]Blood1082484
   Web of Science ®Google Scholar
• TsaiDMaillardIDownsLH2004Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenström’s macroglobulinemiaLeuk Lymphoma45591515160923
   PubMed Web of Science ®Google Scholar
• van OersMHKlasaRMarcusRE2006Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood108329530116873669
   PubMed Web of Science ®Google Scholar
• WeberDRankinKGavinoM2003aThalidomide alone or with dexamethasone for previously untreated multiple myelomaJ Clin Oncol21161912506164
   PubMed Web of Science ®Google Scholar
• WeberDMDimopoulosMADelasalleK2003b2-Chlorodeoxy-adenosine alone and in combination for previously untreated Waldenström’s macroglobulinemiaSemin Oncol30243712720145
   PubMed Web of Science ®Google Scholar
• WeberDChenCNiesvizkyM2006Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009) [abstract]J Clin Oncol18S7521
   Google Scholar
• ZervasKMihouDKatodritouI2006VAD-doxil vs VAD-doxil plus thalidomide as initial treatment in patients with multiple myeloma: a multicenter randomized trial of The Greek Myeloma Study Group [abstract]Blood108794
   Web of Science ®Google Scholar